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Background: Central obesity in relation to insulin resistance is strongly linked to the development of type 2
diabetes. However, data regarding the association between pericardial and peri-aortic adiposity, a potential estimate
of visceral adipose tissue burden, and pre-diabetes status remains unclear.
The aim of this study was to examine whether the degree of pericardial and thoracic peri-aortic adipose tissue,
when quantified by multi-detector computed tomography (MDCT), differs significantly in a normal, pre-diabetic,
and overtly diabetic population.
Methods: We studied 562 consecutive subjects including 357 healthy, 155 pre-diabetic, and 50 diabetic patients selected
from participants who underwent annual health surveys in Taiwan. Pre-diabetes status was defined by impaired fasting
glucose or impaired glucose intolerance according to American Diabetes Association guidelines. Pericardial (PCF) and
thoracic peri-aortic (TAT) adipose tissue burden was assessed using a non-contrast 16-slice multi-detector computed
tomography (MDCT) dataset with off-linemeasurement (Aquarius 3DWorkstation, TeraRecon, SanMateo, CA, USA). Body fat
composition, serum high-sensitivity C-reactive protein (hs-CRP) level and insulin resistance (HOMA-IR) were also assessed.
Results: Patients with diabetes and pre-diabetes had greater volume of PCF (89 ± 24.6, 85.3 ± 28.7 & 67.6 ± 26.7 ml,
p < 0.001) as well as larger TAT (9.6 ± 3.1 ml vs 8.8 ± 4.2 & 6.6 ± 3.5 ml, respectively, p < 0.001) when compared to the normal
group, although there were no significant differences in adiposity between the diabetic and pre-diabetic groups. For those
without established diabetes in our study, increasing TAT burden, but not PCF, appear to correlate with insulin
resistance (HOMA-IR) and hs-CRP in themultivariable models.
Conclusions: Pre-diabetic and diabetic subjects, compared to normoglycemia, were associated with significantly higher
pericardial and peri-aortic adipose tissue burden. In addition, visceral fat accumulation adjacent to the thoracic aorta seemed
to exert a significant impact on insulin resistance and systemic inflammation.
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Central obesity is a risk factor of metabolic syndrome, type
2 diabetes, and hyperlipidemia [1]. In the past decade,
studies have focused on the relationship between meta-
bolic derangements and regional fat deposits, particularly
located in the trunk and waist area independent of total* Correspondence: jotaro3791@gmail.com
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reproduction in any medium, provided the oradiposity. Due to recent advances in radiological tech-
niques, adiposity is readily assessable by computed tomog-
raphy (CT), which may be a more direct measure of tissue
burden. Based on this technique, more and more re-
searches focus on ectopic visceral fat located between the
myocardium and pericardium (pericardial) as well as those
adjacent to the thoracic aorta (peri-aortic) in recent years.
Visceral adipose tissues may play an important role in car-
diovascular diseases and metabolic derangements such as
diabetes, mainly due to the secretion of pro-inflammatory
mediators and cytokines, as a consequence of the liverd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to insulin resistance and systemic inflammation [2,3].
Pre-diabetes is characterized by impaired fasting glu-
cose or impaired glucose tolerance status that reflects
the stage of disordered glucose metabolism between
normoglycemia and diabetes. Pre-diabetes is often under
detected and remains asymptomatic, which may elevate
future risks of diabetes and cardiovascular complications
[4]. Recently, studies have shown that excessive adipose
tissue deposits were closely related to diabetes develop-
ment [5,6]. In addition, exaggerated systemic inflamma-
tion in response to excessive visceral adipose tissue had
been proposed as the main mediating factor in pancreas
functional failure, which plays a key role in type 2 dia-
betes. However, the relationship between visceral adipose
tissue and pre-diabetes status before established clinical
diabetes remains unknown. In this regard, the main ob-
jectives in this study were two-fold; first, we examined
whether there are significant differences and distribution
of PCF, TAT between subjects with pre-diabetes or dia-
betes. Second, we further aimed to examine whether
VAT, either PCF or TAT, may still correlate several clin-




The study was approved by the Institutional Review
Board of Mackay Memorial Hospital, Taipei, Taiwan.
The reference number is 09MMHIS028. All participants
signed written informed consent prior to examinations.
Data were analyzed anonymously. From 2005 to 2009, a
total of 562 participants including 357 healthy, 155 with
pre-diabetes and 50 with type 2 diabetes underwent
health survey and received non-contrast enhanced com-
puted tomography (CT) for assessment of cardiovascular
risks by calculating coronary artery calcium in our cen-
ter. All participants were consecutively enrolled using
the following criteria and divided into three groups: nor-
mal (subjects without hypertension, type 2 diabetes,
hyperlipidemia), pre-diabetes (impaired fasting glucose
(IFG), impaired glucose intolerance, or IFG + IGT) and
type 2 diabetes defined by the American Diabetes Asso-
ciation guidelines [7]. We further excluded subjects who
had typical anginal symptoms during exercise or known
cardiovascular diseases including myocardial infarction,
coronary arterial disease, stroke, atrial fibrillation, prior
hospitalization for congestive heart failure, and periph-
eral arterial disease.
Demographic, anthropometric indices, and laboratory
measures
Detailed physical examination was performed as well as
a thorough review of baseline demographics, medicalhistory including alcohol consumption, smoking, and
physical activity status from structured questionnaires.
All baseline characteristics and anthropometric mea-
sures including age, body height, body weight, waist, and
buttock circumferences were all collected. Standardized
sphygmomanometer cuff-defined resting blood pressures
were measured under resting conditions by medical staff
blinded to other test results. Body surface electrocardio-
gram (ECG) from 12-leads was performed for all subjects.
The estimate of metabolic scores was calculated and pre-
sented as the numbers of abnormal items of the NCEP
Panel III criteria (ATP III ) based on measures of waist cir-
cumference (Female > =80 cm or Male > =90 cm), fasting
glucose (≥ 100 mg/dL), HDL cholesterol (Male < 40 mg/dL
or Female < 50 mg/dL), triglyceride (> 150 mg/dL) and
blood pressure (> 130/85 mmHg). High-sensitivity C-
reactive protein (hs-CRP) levels were determined by using
a highly sensitive, latex particle-enhanced immunoassay
Elecsys 2010 (Roche, Mannheim, Germany).
Glucose metabolism
All sample collection and analytic principles were based
on the standard requirements according to the Clinical
Laboratory Standards Institute (CLSI) guidelines (Speci-
men Choice, Collection, and Handling; Approved Guide-
line H18-A3). To ensure accuracy, samples had repeated
tests in their original tubes within one day to avoid sample
mix up. Normoglycemia was defined as fasting serum glu-
cose (FSG) less than 100 mg/dL. Pre-diabetes was defined
as impaired fasting glucose (IFG) and/or impaired glucose
tolerance (IGT) using the American Diabetes Association
diagnostic criteria [7]. Homeostasis model assessment of
insulin resistance (HOMA-IR) was calculated.
CT scan and quantification of pericardial and thoracic
peri-aortic fat
MDCT of the coronary calcium was performed using a
16-slice MDCT scanner (Sensation 16, Siemens Medical
Solutions, Forchheim, Germany) with 16 x 0.75 mm
collimation, rotation time 420 ms and tube voltage of
120 kV. In one breath-hold, images were acquired from
above the level of the tracheal bifurcation to below the
base of heart using prospectively ECG triggering with
the centre of the acquisition at 70% of the R-R interval.
Visceral adipose tissue, PCF and TAT, was quantified by
MDCT using a dedicated workstation (Aquarius 3D
Workstation, TeraRecon, San Mateo, CA, USA). The
semi-automatic segmentation technique was developed
for quantification of fat volumes. We traced the region
of interest manually and defined fat tissue as pixels
within a window from -195 HU to -45 HU and a win-
dow center at -120 HU. PCF was defined as any adipose
tissue located within the pericardial sac. TAT tissue was
defined as all of the adipose tissue surrounding the
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of the bifurcation of pulmonary arteries with cranial-
caudal coverage of the thoracic aorta. This approach has
previously been validated [6,8,9]. Initially, the intra-
observer and inter-observer coefficient of variation were
4.27%, 4.87% and 6.58%, 6.81% for PCF and TAT, re-
spectively. Both observers performed an independent
reading in a random subset of 40 subjects [6].
Statistical analysis
Continuous data were expressed as the mean and stand-
ard deviation with categorical data expressed as the fre-
quency and proportion of occurrence. Differences in
baseline demographics between groups were tested by
Student t- test with categorical data analyzed by chi-
square or Fisher’s exact test as appropriate. Wilcoxon
non-parametric trend test was used to estimate the trend
of all continuous data and ordinal variables across all or-
dered groups. Univariable logistic regression model was
used to determine the significant factors in the predic-
tion of different metabolic components stratified by both
visceral adipose tissue and hs-CRP tertiles with individ-
ual odds ratio (OR), significance (p value), and 95% con-
fidence interval (CI) reported. A multivariable regression
model in subjects without overt diabetes was conducted
to identify the independent role of visceral adipose in
predicting hs-CRP level and HOMA-IR after adjustment
for baseline clinical variables, various body size esti-
mates, and biochemical data. The variables enrolled in
multivariable models were chosen from those clinical
covariates with significant associations with both visceral
adipose tissue in univariate regressions. Due to collinear-
ity, various body size estimates including BMI, BSA, waist
circumference and body fat composition information were
seqeuntially entered into multivariable models. All data
was analyzed by commercialized software STATA 8.2
package (STATA Corp., College Station, Texas). The sig-
nificance of p level (α-value) for all analysis was two-sided
with 0.05 considered to be statistically significant.
Result
Study sample characteristics
Table 1 describes the demographic anthropometric and
laboratory measures for all subjects included in this
study. A total of 562 participants were enrolled: 357
healthy, 155 with pre-diabetes and 50 with type 2 dia-
betes. Both pre-diabetic and type 2 diabetic subjects
were significantly older with higher blood pressure,
weight, body mass index, waist circumferences, waist-to-
hip ratio than the normal group (all p < 0.001). While no
significant differences in body fat composition were
found between subjects with pre-diabetes and normal
subjects. In addition, triglyceride, fasting glucose, post-
prandial glucose, HbA1c, and HOMA-IR were higherwith a lower HDL cholesterol level in subjects with pre-
diabetes and type 2 diabetes, when compared with nor-
mal ones (all p < 0.001). Patients who had type 2 diabetes
had differed significantly from ones with pre-diabetes
with higher triglyceride, fasting glucose, postprandial
glucose, HbA1c, and HOMA-IR as well as had lower
HDL cholesterol levels. The mean value of PCF and
TAT were 85.3 ± 28.7 & 8.8 ± 4.2 ml in pre-diabetic sub-
jects and 89 ± 24.6 & 9.6 ± 3.1 ml in type 2 diabetic sub-
jects, respectively, and were significantly higher than
both VAT in normals (67.6 ± 26.7 ml & 6.6 ± 3.5 ml,
all p < 0.001). However, both VAT were not different
between pre-diabetic and type 2 diabetic subjects in
Figure 1A and B. The difference among normal, pre-
diabetic, and type 2 diabetic subjects for hs-CRP are
shown in Figure 1C. Subjects with pre-diabetes and type 2
diabetes had higher hs-CRP than normals (all p < 0.001).
There was no significant difference between pre-diabetes
and type 2 diabetes in hs-CRP.
In Table 2, we examined the association between both
VAT and clinical continuous and dichotomous variables
for subjects without established type 2 diabetes (N = 512).
We observed that both VAT were positively associated
with increasing age, and body size estimates (including
BMI, BSA, waist circumference), body fat composition,
systolic blood pressure, and fasting glucose level (all p <
0.001). Furthermore, both VAT were associated with
higher triglyceride, lower HDL cholesterol (both p < 0.001)
and higher LDL cholesterol (both p = 0.004). In Table 3,
we further examined these associations in multivariable
models. Both VAT were associated with higher HOMA-
IR, hs-CRP in univariable model. When age, gender, vari-
ous anthropometric measures, and clinical variables were
further adjusted, we observed that the relationship be-
tween PCF and HOMA-IR, hs-CRP remained borderline
(p > =0.03& <0.1). Increasing TAT burden correlated with
higher HOMA-IR, hs-CRP (all p < 0.05) in the multivari-
able models.
Discussion
Our study provides new insights into the understanding
of the association of visceral adipose tissue, PCF and
TAT, among persons with pre-diabetes, type 2 diabetes,
and normoglycemia. It has been demonstrated that
people with pre-diabetes are at significantly more risk of
developing cardiovascular disease than those with
normoglycemia, and will likely develop type 2 diabetes
without intervention [10]. Central or visceral obesity is
associated with increased insulin resistance, type 2 dia-
betes, hypertension, and hyperlipidemia. In an earlier
work, Stancakova et al. [11] found that an increased
waist circumference, the estimation of visceral adiposity
in male among pre-diabetes. Recently, the association
between diabetes and pericardial/epicardial adiposity
Table 1 The baseline demographic data of participants according to glucose tolerance status
No diabetes Pre-DM DM
N = 357 N = 155 N = 50 Trend P
Age 47.5 ± 7.7 51 ± 8* 53.5 ± 8* <0.001
Gender, female 127 (35.6%) 22 (14%) 12 (24%) <0.001
SBP, mmHg 116.9 ± 15.4 124.6 ± 16.8* 130.2 ± 16.7* <0.001
BMI, kg/m2 23.6 ± 3.1 25.3 ± 3.1* 26.2 ± 3.8* <0.001
BSA, m2 1.72 ± 0.17 1.8 ± 0.16 1.81 ± 0.15 <0.001
WC, cm 81 ± 8.9 86.9 ± 8.3* 89.2 ± 8.7* <0.001
Body Fat, % 24.9 ± 6.2 25.9 ± 6.2 27.3 ± 9.1* 0.08
PCF, ml 68.2 ± 25.5 86.8 ± 26.9 91 ± 24.1 0.005
TAT, ml 6.4 ± 3.3 8.7 ± 4.2 9.5 ± 3.2 0.005
Hypertension 30 (7.7%) 27 (17.5%) 17 (34%) <0.001
Hyperlipidemia 14 (3.6%) 9 (5.8%) 5 (10%) 0.157
Smoking 83 (21.3%) 38 (24.7%) 16 (32%) 0.172
Fasting Glucose, mg/dL 91.6 ± 5.7 103.6 ± 8.6* 159.7 ± 52.7*¥ <0.001
Post-prandial Glucose, mg/dL 99.3 ± 15.7 117.5 ± 30.1* 205.2 ± 85.9*¥ <0.001
HbA1c, % 5.67 ± 0.32 5.93 ± 0.41* 7.52 ± 1.85*¥ <0.001
HOMA-IR 1.25 ± 0.85 1.81 ± 1.09* 3.42 ± 2.2*¥ <0.001
Uric Acid, mg/dL 5.58 ± 1.37 6.35 ± 1.48* 6.04 ± 1.28Υ <0.001
Total Cholesterol, mg/dL 192.5 ± 33.9 195.1 ± 31.9 191.2 ± 39.7 0.79
TG, mg/dL 126.4 ± 65.1 145.3 ± 85.6* 204.6 ± 158.5*¥ <0.001
LDL cholesterol, mg/dL 125.2 ± 31 128.8 ± 31 122.8 ± 32 0.67
HDL cholesterol, mg/dL 53.5 ± 13.5 49.8 ± 13.4* 44.1 ± 9.3*¥ <0.001
BUN, mg/dL 11.9 ± 3.6 12.6 ± 3.4 13.1 ± 3.7Υ <0.001
eGFR, mL/min/1.73 m2 86.9 ± 14.4 81.5 ± 13.3* 84.8 ± 20.2 0.31
ANOVA: *p < 0.05 compared to No Diabetes group, ¥p < 0.05 compared to Pre-DM group, Υp > =0.05 & <0.1 compared to No Diabetes group. BMI body mass index,
HbA1c glycosylated hemoglobin, TG triglyceride, LDL cholesterol low-density cholesterol, HDL cholesterol high-density cholesterol, eGFR estimated glomerular
filtration rate, WC waist circumference.
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amined in several studies [2,6,12]. Using echocardiog-
raphy, Iacobellis et al. observed a significant association
between epicardial fat thickness and fasting blood glu-
cose [12]. However, most of these studies did not show a
significant difference in visceral adiposity in individualsFigure 1 The correlation between normal, pre-diabetic, diabetic subjewith pre-diabetes compared to those with type 2 diabetes.
Our data adds value to previous reports particularly estab-
lishing the association between visceral adiposity and glu-
cose intolerance. Compared to a previous study [12], we
used volume-based measures for assessing region-specific
visceral adipose tissue surrounding the heart and thoraciccts and TAT (A), PCF (B) and hs-CRP (C).
Table 2 The regression models for visceral adipose tissue
with clinical continuous and dichotomous risk variables
for subjects without overt diabetes (N = 512)
PCF (ml) TAT (ml)
β-Coef. p value β-Coef. p value
Age, years 0.34 <0.001 0.34 <0.001
Gender, female −0.19 <0.001 −0.38 <0.001
SBP, mmHg 0.3 <0.001 0.35 <0.001
BMI, kg/m2 0.55 <0.001 0.57 <0.001
BSA, m2 0.45 <0.001 0.51 <0.001
WC, cm 0.58 <0.001 0.64 <0.001
Body Fat, % 0.3 <0.001 0.2 <0.001
SBP, mmHg 0.3 <0.001 0.35 <0.001
Fasting glucose, mg/dL 0.22 <0.001 0.24 <0.001
Total cholesterol, mg/Dl 0.08 0.05 0.05 0.216
HDL cholesterol, mg/dL −0.24 <0.001 −0.36 <0.001
Triglyceride, mg/dL 0.18 <0.001 0.26 <0.001
LDL cholesterol, mg/dL 0.12 0.004 0.12 0.004
eGFR, mL/min/1.73 m2 −0.12 0.04 −0.22 <0.001
Hypertension 0.18 <0.001 0.22 <0.001
Hyperlipidemia 0.09 0.015 0.08 0.027
Exercise −0.08 0.019 −0.11 0.002
Alcohol use 0.004 0.935 0.1 0.015
Smoking 0.06 0.082 0.12 0.001
BMI body mass index, HbA1c glycosylated hemoglobin, TG triglyceride,
LDL cholesterol low-density cholesterol, HDL cholesterol high-density cholesterol,
eGFR estimated glomerular filtration rate, WC waist circumference.
Table 3 The association of visceral adipose tissue with HOMA




Un-adjusted Model 0.21 (<0.001)
Adjusted for BMI
Age, gender, BMI 0.11 (0.089)
Age, gender, BMI, Clinical variables 0.08 (0.266)
Adjusted for BSA
Age, gender, BSA 0.1 (0.056)
Age, gender, BSA, Clinical variables 0.05 (0.472)
Adjusted for WC
Age, gender, WC 0.06 (0.387)
Age, gender, WC, Clinical variables 0.05 (0.514)
Adjusted for body fat %
Age, gender, body fat % 0.14 (0.049)
Age, gender, body fat %, Clinical variables 0.09 (0.209)
BMI body mass index, HbA1c glycosylated hemoglobin, TG triglyceride, LDL choleste
estimated glomerular filtration rate, WC waist circumference.
Clinical variables included age, sex, systolic blood pressure, fasting glucose, triglyce
hyperlipidemia treatment.
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precise measure. Additionally, we extended these previous
observations by showing that PCF and TAT are signifi-
cantly increased in pre-diabetic individuals compared to
normals, with no significant differences observed between
individuals with type 2 diabetes and those with pre-
diabetes. Interestingly, we observed similar trends in the
associations regarding both region-specific VAT and sev-
eral clinical metabolic risks and clinical co-variates as pre-
vious report in our current cohort [13]. This information
suggests progressive metabolic derangements with in-
creasing degrees of visceral adiposity, leading to a progres-
sion from early glycemic dysfunction to the pre-diabetes
stage, in tandem with increasing CVD risk. The volume-
based, three-dimensional CT measurement may be a useful
tool for diabetes-related cardiovascular risk stratification in
selected subjects.
How is visceral fat related to glucose deregulation? In-
creased abdominal visceral adiposity, rather than periph-
eral subcutaneous adiposity, has been associated with
glucose intolerance or frank diabetes [14]. Bays et al. [15]
has hypothesized the pathologic role of visceral adipose
tissue as “sick fat”. This hypothesis states that “adiposo-
pathy” is promoted by positive caloric balance and sed-
entary lifestyle in genetically susceptible individuals.
The accumulation of visceral adipose tissue is associated
with adverse endocrine and immune consequences due
to released substances such as free fatty acids, leptin,
adiponectin, pro-inflammatory agents, and decreased
anti-inflammatory factors. As a result, it often results in
unfavorable glucose metabolism and type-2 diabetes-IR, and Hs-CRP in subjects without overt
l) TAT (ml)
hs-CRP HOMA_IR hs-CRP
β-Coef. (p value) β-Coef. (p value) β-Coef. (p value)
0.16 (0.005) 0.43 (<0.001) 0.27 (<0.001)
0.12 (0.582) 0.42 (<0.001) 0.17 (0.021)
0.14 (0.373) 0.36 (0.005) 0.22 (0.024)
0.18 (0.057) 0.43 (<0.001) 0.19 (0.006)
0.08 (0.381) 0.36 (<0.001) 0.20 (0.026)
0.11 (0.034) 0.41 (<0.001) 0.12 (0.002)
0.06 (0.482) 0.38 (<0.001) 0.20 (0.038)
0.13 (0.659) 0.46 (<0.001) 0.22 (0.002)
0.13 (0.138) 0.40 (<0.001) 0.25 (0.007)
rol low-density cholesterol, HDL cholesterol high-density cholesterol, eGFR
ride, HDL cholesterol, exercise, alcohol use, smoking, and hypertension or
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beta-cell deterioration that leads to glucose intolerance
[17]. Evidence from previous studies [18,19] has demon-
strated that adverse metabolic derangements of excess
fat are more closely related to the location than to the
amount. Visceral adipose tissue and pericardial fat exhibit
differences in leptin, adiponectin, and IL-6 secretion. How-
ever, a comprehensive characterization of pericardial and
peri-aortic adipose tissue have not been established [20].
In our study, we also found that an interaction between
regional-specific visceral adipose tissue and systemic in-
flammation in subjects without established diabetes, with
only TAT but not PCF having a pronounced effect on
HOMA-IR and hs-CRP through multivariate regression
analysis. These results suggest that perivascular fat depos-
ition can be implicated in systemic inflammation more
strongly than pericardial fat deposition. Several possible
mechanisms could be put forward in regard to the differ-
ential behavior of region-specific visceral adipose tissue.
First, PCF has been confined to the pericardial sac, but
TAT surrounds the aorta, which is more prone to sys-
temic effects via adventitial inflammation that traverse
the arterial wall [21] and systemic inflammation impact-
ing HOMA-IR and hs-CRP. Second, relatively healthy
subjects presenting for health checkups without definite
type 2 diabetes in our subanalyses may explain the lack
of significant correlation of hs-CRP, HOMA-IR and PCF
in multivariate analyses, which differ from those ob-
tained in studies on diseased subjects [9,22].
Our study suggests that PCF and TAT have strong as-
sociations with glucose intolerance and type 2-diabetes.
However, this cross-sectional study cannot assess clinical
outcomes with respect to the development of type 2 DM
since a large pre-diabetic population and long term fol-
low up is needed for adequate statistical analysis. Future
prospective trials are required to assess the prognostic
value of CT-measured region-specific VAT for compari-
son with traditional risk factors.
There are several limitations of our study. Firstly, we in-
cluded fewer women than men (male/female: 401/161),
which may limit its generalizability and hardly performing
the subsequent analyses for men and women separately,
In addition, as in every cross-sectional study, we cannot
pride the follow up data related to the relationship be-
tween region-specific VAT and progression of glycemic
dysfunction. Future longitudinal studies of visceral adipose
tissue burden in this population may help to clarify these
relationships.
Conclusions
Our data indicated that pre-diabetic status was associ-
ated with significantly higher pericardial and peri-aortic
adipose tissues than normal subjects, which is actually
comparable to established diabetic patients. In addition,in subjects without established diabetes, visceral fat adja-
cent to the aorta seemed to exert effects on insulin
resistance and systemic inflammation. We believe that
the major implications of this study are as follows: (1)
increased specific regional visceral fat deposits may be
related to pre-diabetes and could be used as additional
information for cardiovascular risk stratification during
the early stages of glucose dysfunction; (2) peri-aortic fat
may exert a more significant systemic effect than peri-
cardial adipose tissue.
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